Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period

Trial Profile

Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Delamanid (Primary) ; Antituberculars
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 11 Apr 2022 Results from phase 1 and phase 2 trials (NCT01856634 and NCT01859923) published in the Antimicrobial Agents and Chemotherapy
    • 29 Nov 2021 Results (n=37) of population PK analysis to characterize the PK of delamanid in the pediatric population with data collected in Trials NCT01856634 and NCT01859923 and to calculate doses for pediatric participants across the entire age range, i.e between 0-17 years of age, that will result in systemic exposures of delamanid comparable to that of the approved dose in adults (100 mg BID), published in the Antimicrobial Agents and Chemotherapy.
    • 26 Jul 2021 According to an Otsuka Pharmaceutical media release, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of Deltyba 25 mg dispersible tablets (delamanid) for use as part of an appropriate combination regimen for pulmonary MDR-TB in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top